✦ LIBER ✦

Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies

✍ Scribed by Aggarwal, Rahul; Grabowsky, Jennifer; Strait, Noah; Cockerill, Alyson; Munster, Pamela

Book ID: 125344341
Publisher: Springer
Year: 2014
Tongue: English
Weight: 886 KB
Volume: 74
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-014-2510-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activation of the PI3K/Akt/mTOR pathway

Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder

✍ Chih-Hao Sun; Yen-Hwa Chang; Chin-Chen Pan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 512 KB

366 Phase I Dose-escalation Study of the

366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors

✍ Ahnert, J. Rodon; Burris, H.A.; Schellens, J.H.M.; Schuler, M.; Goodman, O.; Bri 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 62 KB

1478 POSTER Dual inhibition of mTOR and

1478 POSTER Dual inhibition of mTOR and of the Insulin like growth factor receptor-1 completely blocks the PI3K/Akt/mTOR pathway and results in a supra-additive anti-tumor effect: a mechanistic-based combination approach

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Associations between Single-Nucleotide P

Associations between Single-Nucleotide Polymorphisms in the PI3K-PTEN-AKT-mTOR Pathway and Increased Risk of Brain Metastasis in Patients with Non-Small Cell Lung Cancer

✍ Li, Q.; Yang, J.; Yu, Q.; Wu, H.; Liu, B.; Xiong, H.; Hu, G.; Zhao, J.; Yuan, X. 📂 Article 📅 2013 🏛 American Association for Cancer Research 🌐 English ⚖ 457 KB

216 POSTER A phase I dose-escalation stu

216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors

✍ B. Markman; P.M. LoRusso; A. Patnaik; E. Heath; A.D. Laird; B. van Leeuwen; K.P. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 72 KB

619 Results of the First-in-human Phase

619 Results of the First-in-human Phase I Study of GDC-0068, an Akt Inhibitor That Demonstrates Safe and Sustained Targeting of the PI3K/Akt Pathway in Patients (pts) with Advanced Solid Tumors

✍ Cervantes, A.; Saura, C.; Roda, D.; Dienstmann, R.; Rosello, S.; Carles, J.; Fun 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB